AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
16.8 C
New York
Wednesday, October 21, 2026

Tag: documents

Boston Beer Reports Second Quarter Financial Results

BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the second quarter ended June 28, 2025. Key results were:

Christian Dior: Solid results in the first half of 2025 despite the prevailing environment

Solid results in the first half of 2025
despite the prevailing environment
. Revenue: €40 billion
. Profit from recurring operations: €9 billion
. Free cash flow: €4 billion

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Valeo – Résultats du 1er semestre 2025

CP résultats S1 2025 Wiztrust

COMMUNIQUÉ DE PRESSE EN DATE DU 24 JUILLET 2025 RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIETE...

COMMUNIQUÉ DE PRESSE EN DATE DU 24 JUILLET 2025 RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE

La Rosa Holdings Corp. Extinguishes Majority of Outstanding Warrants Through Exchange Agreements, Strengthening Balance Sheet

Company Regains Nasdaq Compliance with Minimum Bid Price Requirement
Company Regains Nasdaq Compliance with Minimum Bid Price Requirement

Real Estate Split Corp. Class A Distribution

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Real Estate Split Corp. (TSX: RS) (the “Fund”) is pleased to announce that a distribution for July 2025 will be payable to Class A shareholders of Real Estate Split Corp. as follows:

Middlefield Global Infrastructure Dividend ETF Distributions

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Middlefield Global Infrastructure Dividend ETF (TSX: MINF) (the “Fund”) is pleased to announce that distributions for the third quarter of 2025 will be payable to unitholders of Middlefield Global Infrastructure Dividend ETF as follows:

Frankie Muniz Joins Forces with Worksport to Champion American Energy Innovation

Former ‘Malcolm in The Middle’ Actor, and Professional NASCAR Driver Enters Brand Partnership with Worksport

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDocuments